2.27
price down icon6.58%   -0.16
after-market After Hours: 2.35 0.08 +3.52%
loading
Aldeyra Therapeutics Inc stock is traded at $2.27, with a volume of 2.12M. It is down -6.58% in the last 24 hours and up +38.41% over the past month. Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$2.43
Open:
$2.41
24h Volume:
2.12M
Relative Volume:
1.43
Market Cap:
$136.93M
Revenue:
-
Net Income/Loss:
$-27.37M
P/E Ratio:
-4.9868
EPS:
-0.4552
Net Cash Flow:
$-25.99M
1W Performance:
+26.11%
1M Performance:
+38.41%
6M Performance:
-51.39%
1Y Performance:
-43.25%
1-Day Range:
Value
$2.25
$2.5298
1-Week Range:
Value
$1.71
$2.53
52-Week Range:
Value
$1.07
$6.175

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name
Name
Aldeyra Therapeutics Inc
Name
Phone
781-761-4904
Name
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Name
Employee
7
Name
Twitter
@aldeyraaldx
Name
Next Earnings Date
2026-08-06
Name
Latest SEC Filings
Name
ALDX's Discussions on Twitter

Compare ALDX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ALDX icon
ALDX
Aldeyra Therapeutics Inc
2.27 128.48M 0 -27.37M -25.99M -0.4552
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
528.04 126.07B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
654.27 65.37B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
939.68 57.70B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
312.78 40.19B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
189.24 39.82B 742.00K -1.37B -1.07B -7.0731

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-18-26 Downgrade H.C. Wainwright Buy → Neutral
Apr-03-24 Upgrade Oppenheimer Perform → Outperform
Apr-02-24 Resumed H.C. Wainwright Buy
Apr-27-22 Resumed H.C. Wainwright Buy
Feb-08-21 Initiated H.C. Wainwright Buy
Dec-16-20 Initiated Berenberg Buy
Oct-30-20 Initiated Jefferies Buy
Oct-16-20 Initiated BTIG Research Buy
Sep-22-20 Initiated Alliance Global Partners Buy
May-12-20 Initiated Oppenheimer Outperform
Dec-04-18 Initiated Citigroup Buy
Sep-26-18 Reiterated Cantor Fitzgerald Overweight
Sep-13-18 Initiated Janney Buy
Jan-26-18 Initiated Seaport Global Securities Buy
Sep-26-16 Initiated H.C. Wainwright Buy
Jul-01-16 Initiated Stifel Buy
Jul-01-15 Initiated Canaccord Genuity Buy
Mar-25-15 Initiated Chardan Capital Markets Buy
Mar-20-15 Reiterated H.C. Wainwright Buy
Nov-18-14 Initiated H.C. Wainwright Buy
Jun-19-14 Initiated Aegis Capital Buy
View All

Aldeyra Therapeutics Inc Stock (ALDX) Latest News

pulisher
Jun 30, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jun 30, 2026
pulisher
Jun 30, 2026

ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Jun 30, 2026
pulisher
Jun 29, 2026

Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Dynamic Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 3000E Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell Small Cap Completeness Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 3000 Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 28, 2026
pulisher
Jun 28, 2026

137 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 28, 2026
pulisher
Jun 27, 2026

Why Did ALDX Stock Tank 70% Today? - Stocktwits

Jun 27, 2026
pulisher
Jun 27, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review

Jun 27, 2026
pulisher
Jun 27, 2026

Price to book forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView

Jun 27, 2026
pulisher
Jun 26, 2026

Price to book forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

ALDX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to EBITDA forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to EBITDA forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to revenue forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to revenue forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Aldeyra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALDX) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Aldeyra appoints Darlene Deptula-Hicks to board of directors By Investing.com - Investing.com Nigeria

Jun 26, 2026
pulisher
Jun 26, 2026

Aldeyra Therapeutics, Inc. Actuals & Estimates (DUS:137) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to earnings forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to sales forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

Enterprise value to EBIT forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Price to earnings forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - ACCESS Newswire

Jun 25, 2026
pulisher
Jun 25, 2026

Enterprise value to EBIT forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Aldeyra Therapeutics, Inc. Actuals & Estimates (MUN:137) - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc - The National Law Review

Jun 25, 2026
pulisher
Jun 25, 2026

Aldeyra Therapeutics Inc (ALDX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 25, 2026
pulisher
Jun 24, 2026

Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 24, 2026
pulisher
Jun 23, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 23, 2026
pulisher
Jun 21, 2026

Precision Trading with Aldeyra Therapeutics Inc. (ALDX) Risk Zones - Stock Traders Daily

Jun 21, 2026
pulisher
Jun 21, 2026

2026-06-21 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation | NDAQ:ALDX | Press Release - Stockhouse

Jun 21, 2026
pulisher
Jun 18, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire

Jun 18, 2026
pulisher
Jun 17, 2026

Aldeyra Therapeutics Inc (ALDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Aldeyra Therapeutics Inc (ALDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Aldeyra Therapeutics Inc (ALDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Aldeyra Therapeutics Inc (ALDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Aldeyra Therapeutics Inc (ALDX) Institutional Confidence - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Aldeyra Therapeutics Inc (ALDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Aldeyra Therapeutics Inc (ALDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026
pulisher
Jun 16, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire

Jun 16, 2026
pulisher
Jun 15, 2026

ALDX News | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill

Jun 15, 2026
pulisher
Jun 14, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Connect - ACCESS Newswire

Jun 14, 2026
pulisher
Jun 11, 2026

Aldeyra Therapeutics (ALDX) grants director options on 73,318 shares - Stock Titan

Jun 11, 2026

Aldeyra Therapeutics Inc Stock (ALDX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Aldeyra Therapeutics Inc Stock (ALDX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
DOUGLAS RICHARD
Director
Mar 19 '26
Buy
1.40
70,000
98,000
195,000
Alfieri Michael
Principal Financial Officer
Mar 18 '26
Buy
1.42
5,000
7,100
7,500
Alfieri Michael
Principal Financial Officer
Aug 13 '25
Buy
5.30
2,500
13,250
2,500
Machatha Stephen
Chief Development Officer
Aug 11 '25
Sale
5.15
22,073
113,713
221,799
$97.55
price up icon 3.86%
$35.13
price up icon 0.29%
$57.77
price up icon 3.57%
ONC ONC
$297.65
price up icon 2.38%
$79.76
price up icon 10.01%
$189.24
price up icon 0.92%
Cap:     |  Volume (24h):